Clomipramine

證據等級: L5

預測適應症: 10 個

Clomipramine: From Obsessive-Compulsive Disorder to Anxiety Disorder

One-Sentence Summary

Clomipramine is a tricyclic antidepressant (TCA) with the most potent serotonin reuptake inhibition among its class, historically established internationally as a first-line pharmacotherapy for obsessive-compulsive disorder (OCD) and depression, though it carries no current US FDA-approved NDA on record. The TxGNN model predicts it may be effective for Anxiety Disorder, with 19 clinical trials and 20 publications currently supporting this direction. Evidence strength is rated L1, anchored by completed Phase 3/4 randomized controlled trials, two Cochrane systematic reviews, and a 2023 Cochrane network meta-analysis in panic disorder.

Quick Overview

Item	Content
Original Indication	OCD and depression (established internationally; no current US FDA NDA on file)
Predicted New Indication	Anxiety Disorder
TxGNN Prediction Score	99.93%
Evidence Level	L1
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack (DrugBank MOA query returned no data). Based on established pharmacology, clomipramine is the tricyclic antidepressant with the strongest serotonin reuptake inhibition (SRI) activity in its class. Its efficacy in OCD — an anxiety-spectrum disorder — has been proven through landmark Phase 3 randomized controlled trials (notably the Clomipramine Collaborative Study Group), cementing its first-line status globally. In addition to 5-HT reuptake blockade, clomipramine inhibits norepinephrine (NE) reuptake, which contributes to suppression of generalized anxiety symptoms beyond OCD.

The mechanistic link between OCD and the broader anxiety disorder category is well-supported: 5-HT reuptake inhibition reduces fear responses mediated by the amygdala and modulates the orbitofrontal cortex–caudate nucleus circuit central to OCD. The same 5-HT/NE dual mechanism applies directly to panic disorder, where multiple direct RCTs spanning 1984–1999 and a 2023 Cochrane network meta-analysis (PMID 38014714) confirm clinical benefit. Agoraphobia, often comorbid with panic disorder, has also been directly studied with clomipramine (PMID 6373161, PMID 2651491).

The TxGNN prediction of 99.93% likelihood reflects the knowledge graph’s recognition of this mechanistic proximity — clomipramine’s established efficacy across OCD, panic disorder, and phobic anxiety creates a well-connected node cluster that maps naturally onto the broader anxiety disorder category.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00564564	Phase 4	Completed	21	Open-label RCT directly comparing quetiapine augmentation vs. clomipramine augmentation of SSRI in OCD patients with inadequate SSRI response; supports clomipramine as an evidence-based augmentation strategy
NCT00004310	Phase 2	Unknown	76	RCT evaluating IV pulse-loading vs. oral clomipramine followed by 12-week maintenance in OCD; specifically targets treatment-resistant cases with high relevance to refractory anxiety disorder
NCT00466609	Phase 4	Completed	54	Double-blind, double-dummy RCT comparing fluoxetine + quetiapine vs. fluoxetine + clomipramine augmentation in SSRI-nonresponsive OCD; provides controlled efficacy data for clomipramine combination use
NCT02431845	NA	Recruiting	200	Pharmaco(epi)genetic, proteomic, and microbiomic study in OCD; clomipramine as one of the study medications, providing mechanistic insight into biomarkers of treatment response
NCT01404871	NA	Completed	26	RCT comparing clomipramine vs. escitalopram in OCD to identify clinical and biological predictors of medication response; informs personalized prescribing
NCT03299166	Phase 2/3	Completed	426	Double-blind, placebo-controlled RCT of troriluzole adjunct therapy in OCD patients with inadequate response to SSRI, clomipramine, or venlafaxine; large trial confirming clomipramine as standard comparator
NCT00254735	Phase 3	Completed	44	Placebo-controlled pilot RCT evaluating quetiapine added to SSRI/clomipramine baseline in adult OCD; supports clomipramine as backbone therapy
NCT00074815	Phase 3	Completed	124	RCT testing whether CBT improves SRI (including clomipramine) treatment outcomes in pediatric OCD partial responders; demonstrates clomipramine utility in younger population
NCT01148316	NA	Completed	144	Adaptive treatment strategies for pediatric OCD and psychiatric disorders; clomipramine and SSRIs as approved pharmacotherapy options; up to 30% of patients may not respond, highlighting need for alternatives
NCT04708834	Phase 3	Terminated	772	Long-term open-label safety study of troriluzole adjunct in OCD with clomipramine as permitted background therapy; largest OCD trial in evidence pack (terminated early, safety data partially available)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38014714	2023	Network Meta-analysis	Cochrane Database Syst Rev	Comprehensive network meta-analysis of all pharmacological treatments for adult panic disorder; evaluates relative efficacy and acceptability of clomipramine vs. SSRIs and other agents
34582562	2021	Cochrane Systematic Review	Cochrane Database Syst Rev	Updated Cochrane review on pharmacotherapy for trichotillomania (OCD-spectrum disorder); systematic evaluation of clomipramine efficacy and tolerability vs. comparators
24214100	2013	Cochrane Systematic Review	Cochrane Database Syst Rev	Earlier Cochrane review on pharmacotherapy for trichotillomania; first systematic evaluation establishing evidence base for clomipramine in OCD-spectrum conditions
1474179	1992	RCT	J Clin Psychopharmacol	Placebo-controlled 4-arm RCT comparing clomipramine, clonazepam, clonidine, and diphenhydramine (control) in OCD; demonstrates significant clomipramine superiority over control
10665629	1999	RCT	J Clin Psychiatry	12-week, placebo-controlled RCT directly comparing paroxetine, clomipramine, and cognitive therapy in DSM-III-R panic disorder with or without agoraphobia
27663940	2016	Meta-analysis	J Am Acad Child Adolesc Psychiatry	Meta-analysis of early treatment response to SSRIs and clomipramine in pediatric OCD; clomipramine shows numerically superior efficacy with distinct time course
2178909	1990	Pharmacological Review	Drugs	Comprehensive overview of clomipramine pharmacological properties and clinical use in OCD and panic disorder; short-term trials confirm superiority over older TCAs for these indications
3887336	1985	Review	Psychiatr Clin North Am	Foundational review establishing clomipramine as the first effective pharmacotherapy for OCD; discusses biological basis including serotonergic mechanism and genetic factors
7795952	1995	Review	J Child Adolesc Psychiatr Nurs	Review of clomipramine in pediatric OCD management; covers dosing, SRI mechanism, response assessment, and clinical monitoring including cardiac and hepatic considerations
22204483	2012	Review	Curr Top Med Chem	Review of treatment strategies for OCD and panic disorder/agoraphobia; positions clomipramine within the full pharmacotherapy landscape including SSRIs and combination approaches

US Market Information

Clomipramine (DrugBank ID: DB01242) currently holds no FDA-approved New Drug Applications (NDAs) in the United States. The drug is not marketed in the US market as of the data cutoff (2026-06-15). Clomipramine is approved and marketed in numerous other jurisdictions — including European Union member states and Japan — for indications including OCD, depressive illness, and panic disorder. Any clinical development or use in the US would require an Investigational New Drug (IND) application or equivalent regulatory pathway.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Evidence for clomipramine across the anxiety disorder spectrum is robust and spans multiple levels: completed Phase 3/4 RCTs in OCD, direct placebo-controlled RCTs in panic disorder and agoraphobia, two Cochrane systematic reviews in OCD-spectrum conditions, and a 2023 Cochrane network meta-analysis in panic disorder — collectively placing the evidence at L1. The dual 5-HT/NE reuptake mechanism provides strong, well-characterized biological plausibility for the TxGNN prediction. The “Guardrails” designation reflects the lack of US FDA approval, the well-known TCA safety profile (QTc prolongation, anticholinergic burden, seizure threshold lowering), and the need for structured safety monitoring.

To proceed, the following is needed:

Detailed MOA data from DrugBank (remediation: DrugBank API query)
US-equivalent package insert or authoritative safety labeling from a jurisdiction where clomipramine is approved (EU SmPC or Japan package insert) — required to complete key warnings and contraindications assessment
Drug–drug interaction profile (DDI query returned no results; manual review or alternative DDI database query recommended)
Cardiac safety monitoring protocol: baseline ECG with QTc assessment, periodic monitoring during titration
Population-specific dosing guidance for high-risk groups (elderly patients, pediatric patients, those with pre-existing cardiac disease or seizure disorders)
Regulatory pathway assessment for potential US IND filing, given zero current NDA holders
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.